propel: final os of first-line abiraterone plus olaparib for mcrpc
Published 1 year ago • 296 plays • Length 4:08Download video MP4
Download video MP3
Similar videos
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
5:36
propel trial
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
1:27
hrqol and pain outcomes in mcrpc: abi ala vs abi pbo in propel
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
9:23
drs. armstrong, wallis on ai biomarkers and hrqol for localized prostate cancer, mcrpc
-
3:47
elucidating hrrm status in patients with mcrpc in the propel trial
-
2:45
biomarker analysis and updated results from propel
-
1:19
highlights in prostate cancer from esmo
-
4:30
profound: olaparib for hrr mcrpc
-
4:21
phase ii results of olaparib and abiraterone for mcrpc
-
1:40
dr. maughan discusses abiraterone plus olaparib in mcrpc
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
1:15
brcaaway: abiraterone with olaparib in mcrpc with hrr mutations
-
4:24
emuc18: stampede trial